Early manifestations in multiple-low-dose streptozotocin-induced diabetes in mice

Pancreas

Volumn 30, Issue 4, 2005, Pages 318-324

  Karabatas, Liliana M ^a   Pastorale, Claudia ^a   De Bruno, Lidia Fabiano ^a   Maschi, Fabricio ^b   Pivetta, Omar H ^c   Lombardo, Yolanda B ^d   Chemes, Héctor ^a   Basabe, Juan C ^a  

^a HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

^b UNIVERSIDAD NACIONAL DE LA PLATA   (Argentina)

^c Hospital Bernardino Rivadavia   (Argentina)

^d UNIVERSIDAD NACIONAL DEL LITORAL   (Argentina)

Author keywords

Diabetic mice; Immune alterations; Insulin secretion

Indexed keywords

INSULIN; STREPTOZOCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE SEVERITY; HISTOPATHOLOGY; HYPERGLYCEMIA; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULITIS; MALE; MONONUCLEAR CELL; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; SPLEEN CELL; STREPTOZOCIN DIABETES;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; AUTOIMMUNITY; BLOOD GLUCOSE; CELLS, CULTURED; COCULTURE TECHNIQUES; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; HYPERGLYCEMIA; INSULIN; INSULIN-SECRETING CELLS; MALE; MICE; MICE, INBRED C57BL; RATS; RATS, WISTAR; SPLEEN; STREPTOZOCIN;

EID: 17844368647     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mpa.0000161888.02244.7a     Document Type: Article

References (36)

1. Castaño L, Eisenbarth G. Type I diabetes: a chronic autoimmune disease of human, mouse and rat. Annu Rev Immunol. 1990;8:647-676.
2. Like AA, Rossini AA. Streptozocin-induced pancreatic insulitis: new model of diabetes mellitus. Science. 1976;193:415-417.
3. Lukic ML, Stosic-Grujicic S, Shahin A. Effector mechanisms in low-dose streptozotocin-induced diabetes. Dev Immunol. 1998;6:119-128.
4. Kolb H, Kröncke KD. IDDM. Lessons from the low-dose streptozocin model in mice. Diabetes Rev. 1993;1:116-126.
5. Arata M, Bruno L, Pastorale C, et al. Effect of modified diabetic splenocytes on mice injected with splenocytes from multiple low-dose streptozotocin diabetic donors. Exp Biol Med. 2001;226:898-905.
6. Pastorale C, Arata M, Caminos A, et al. Effect of modified diabetic splenocytes on mice injected with multiple low-dose streptozotocin. Exp Biol Med. 2002;227:282-289.
7. Müller A, Schott-Ohly P, Dohle C, et al. Differential regulation of Thl-type and Th2-type cytokine profiles in pancreatic islets of C57BL/6 and BALB/c mice by multiple low doses of streptozotocin. Immunobiology. 2002;205:35-50.
8. Buschard K, Rygaard J. Pasive transfer of streptozotocin induced diabetes mellitus with spleen cells. Acta Pathol Microbiol Scand [C]. 1977;85: 469-472.
9. Arata M, Fabiano de Bruno L, Goncalvez Volpini W, et al. Beta-cell function in mice injected with mononuclear splenocytes from multiple-dose streptozotocin diabetic mice. Proc Soc Exp Biol Med. 1994;206:76-82.
10. Lacy PE, Kostianovsky M. Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes. 1967;16:35-39.
11. Phillips HJ. Dye exclusion test for cell viability. In: Kruse G, Patterson C, eds. Tissue: Methods and Applications. New York: Academic Press; 1973: 406-408.
12. Ono J, Takaki R, Fukuma M. Preparation of single cells from pancreatic islets of adult rats by the use of dispase. Endocrinol Jpn. 1977;24:265-270.
13. Boitard C, Debray-Sachs M, Plouplard A, et al. Lymphocytes from diabetics suppress insulin release in vitro. Diabetologia. 1981;21:41-46.
14. Zavala AV, Fabiano de Bruno LE, Cardoso AI, et al. Cellular and humoural autoimmunity markers in Type 2 (non-insulin-dependent) diabetic patients with secondary drug failure. Diabetologia. 1992;35:1159-1164.
15. Karabatas LM, Fabiano de Bruno L, Pastorale C, et al. Branched-chain amino acid-enriched diet: effects on insulin secretion and cellular immune aggression. Proc Soc Exp Biol Med. 2000;224:159-165.
16. Burr IM, Balant L, Stauffacher W, et al. Dynamic aspects of proinsulin release from perifused rat pancreas. Lancet. 1969;2:882-883.
17. Weibel ER, Kistler GS, Scherle WF. Practical stereological methods for morphometric cytology. J Cell Biol. 1966;30:23-38.
18. Herbert V, Lau K, Gottlieb CW, et al. Coated charcoal immunoassay of insulin. J Clin Endocrinol Metab. 1965;25:1375-1384.
19. O'Brien BA, Harmon BV, Cameron DP, et al. Beta-cell apoptosis is responsible for the development of IDDM in the multiple low-dose streptozotocin model. J Pathol. 1996;178:176-181.
20. Wang Z, Gleichmann H. GLUT2 in pancreatic islets. Crucial target molecule in diabetes induced with multiple low doses of streptozotocin in mice. Diabetes. 1998;47:50-56.
21. Rabinovitch A. Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM: Therapeutic intervention by immunostimulation. Diabetes. 1994;43:613-621.
22. Thorvaldson L, Holstad M, Sandler S. Cytokine release by murine spleen cells following multiple low dose streptozotocin-induced diabetes and treatment with a TNF-alpha transcriptional inhibitor. Int Immunopharmacol. 2003;3:1609-1617.
23. Eisenbarth GS. Type I diabetes mellitus: a chronic autoimmune disease. N Engl J Med. 1986;314:1360-1368.
24. Yang Z, Chen M, Fialkow LB, et al. The novel anti-inflammatory compound, lisofylline, prevents diabetes in multiple low-dose streptozotocin-treated mice. Pancreas. 2003;26:E99-E104.
25. Maksimovic-Ivanic D, Trajkovic V, Miljkovic DJ, et al. Down-regulation of multiple low dose streptozotocin-induced diabetes by mycophenolate mofetil. Clin Exp Immunol. 2002;129:214-223.
26. Kantwerk-Funke G, Burkart V, Kolb H. Low dose streptozotocin causes stimulation of the immune system and of anti-islet cytotoxicity in mice. Immunology. 1991;86:266-270.
27. Cockfield SM, Ramassar V, Urmson J, et al. Multiple low-dose streptozotocin-induced systemic MHC expression in mice triggering T cells in release IFN-γ. J Immunol. 1989;142:1120-1128.
28. Iglesias A, Murga M, Laresgoiti U, et al. Diabetes and exocrine pancreatic insufficiency in E2F1/E2F2 double-mutant mice. J Clin Invest. 2004;113: 1398-1407.
29. Li Y, Hansotia T, Yusta B, et al. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem. 2003;278:471-478.
30. Johnson JD, Ahmed NT, Luciani DS, et al. Increased islet apoptosis in Pdx1+/- mice. J Clin Invest. 2003;111:1147-1160.
31. Arata M, Fabiano de Bruno L, Goncalvez Volpini W, et al. Insulin secretion by pancreas of athymic mice injected with peripheral mononuclear cells from insulin-dependent diabetic patients. Metabolism. 1995; 44:1435-1441.
32. Karabatas LM, Fabiano de Bruno L, Pastorale CF, et al. Inhibition of nitric oxide generation: normalization of in vitro insulin secretion in mice with multiple low-dose streptozotocin and in mice injected with mononuclear splenocytes from diabetic syngeneic donors. Metabolism. 1996;45:940-946.
33. Boitard C, Chatenoud L, Debray-Sach N. In vitro inhibition of pancreatic beta cell function by lymphocytes from diabetics with associated autoimmune diseases: a T cell phenomenon. J Immunol. 1982;129:2529-2531.
34. Enghofer M, Bojunga J, Ludwig R, et al. Lymphocyte transfer in streptozotocin-induced diabetes: adhesion of donor cells to islet endothelium. Am J Physiol. 1998;274:E928-E935.
35. Herold KC, Vezys V, Sun Q, et al. Regulation of cytokine production during development of autoimmune diabetes induced with multiple low doses of streptozotocin. J Immunol. 1996;156:3521-3527.
36. McEvoy RC, Andersson J, Sandler S, et al. Multiple low-dose streptozotocin-induced diabetes in the mouse: evidence for stimulation of a cytotoxic cellular immune response against an insulin-producing beta cell line. J Clin Invest. 1984;74:715-722.